<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766921</url>
  </required_header>
  <id_info>
    <org_study_id>V89_13</org_study_id>
    <nct_id>NCT01766921</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects</brief_title>
  <official_title>A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived
      influenza vaccine in elderly subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.</measure>
    <time_frame>Baseline (day 1) and Three weeks after 2nd vaccination (day 43)</time_frame>
    <description>The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.
The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 60%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</measure>
    <time_frame>Three weeks after 2nd vaccination (day 43)</time_frame>
    <description>Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.
Seroconversion is defined as, a postvaccination titer ≥40 in subjects with a prevaccination HI titer &lt;10; or in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 30%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events, After Any Vaccination.</measure>
    <time_frame>From day 1 through day 7 after any vaccination.</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following vaccination with either low or high dose of aH5N1c vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.</measure>
    <time_frame>Day 1 through day 387 after any vaccination</time_frame>
    <description>Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with aH5N1c vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios (GMR) Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.</measure>
    <time_frame>Day 1; day 22; day 43 and day 387</time_frame>
    <description>Immunogenicity was measured as the GMR. The ratio of postvaccination to prevaccination HI geometric mean titers (GMTs) is reported.
The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is &gt;2.0 for subjects &gt;60 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain</measure>
    <time_frame>Day 1, day 22, day 43 and day 387.</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of subjects achieving HI titers &gt;40, three weeks after second vaccination with aH5N1c according to the CHMP criterion.
The European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;60%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain</measure>
    <time_frame>Day 22, day 43 and day 387</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, three weeks after receiving two injections of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.
Seroconversion is defined as a postvaccination titer ≥40 in subjects with a prevaccination HI titer &lt;10; or in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion is &gt;30%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1393</enrollment>
  <condition>Pandemic H5N1 Influenza</condition>
  <arm_group>
    <arm_group_label>aH5N1c - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aH5N1c - Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted H5N1 pandemic influenza vaccine</intervention_name>
    <description>Comparison of two doses of aH5N1c vaccine</description>
    <arm_group_label>aH5N1c - High dose</arm_group_label>
    <arm_group_label>aH5N1c - Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy elderly subjects ≥65 years,

          2. Individuals willing to provide written informed consent,

          3. Individuals in good health,

          4. Individuals willing to allow for their serum samples to be stored beyond the study
             period.

        Exclusion Criteria:

          1. Individuals not able to understand and follow study procedures,

          2. History of any significant illness,

          3. History of any serious chronic medical condition or progressive disease,

          4. Presence of medically significant cancer,

          5. Known or suspected impairment/alteration of immune function,

          6. Presence of any progressive or severe neurologic disorder,

          7. Presence of any bleeding disorders or conditions that prolongs bleeding time,

          8. History of allergy to vaccine components,

          9. Receipt of any other investigational product within 30 days prior to entry into the
             study,

         10. History of previous H5N1 vaccination,

         11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into
             the study,

         12. Receipt of any other vaccine within 2 weeks prior to entry into the study

         13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended
             study vaccination,

         14. Body mass index (BMI) ≥ 35 kg/m2,

         15. History of drug or alcohol abuse,

         16. Any planned surgery during study period,

         17. Individuals conducting the study and their immediate family members,

         18. Individuals with behavioral or cognitive impairment or psychiatric diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1 Tatum Highlands Med Ass PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5 Broward Research Group Pembroke Pines</name>
      <address>
        <city>Florida</city>
        <state>Florida</state>
        <zip>33206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>7 Heartland Rsrch Ass LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9 Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3 Saint Louis University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2 Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>6 Regional Clinical Research Endwell,</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Benchmark Medical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>12 Tekton Research</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8 J. Lewis Research Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10 Foothill Family Clinic</name>
      <address>
        <city>South Cottonwood Heights</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11 Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>42 Hunter Clinical Research</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44 Wesley Research Institute Clinical Trials Center</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40 CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>41 Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45 Childrens Clin Rsrch Facility</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6872</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>50 Southern Clinical Trials</name>
      <address>
        <city>Beckenham</city>
        <state>Christchurch</state>
        <zip>8244</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>51 Riccarton Clinic</name>
      <address>
        <city>Riccarton</city>
        <state>Christchurch</state>
        <zip>8041</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>72 Faculty of Medicine, Chulalongkorn University - Queen Saovabha Memorial Institute</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71 Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>73 Siriraj Clinical Research Ctr</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>74 Chiang Mai Uni Hospital Clinical Trial Center</name>
      <address>
        <city>Bangkok</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <results_first_submitted>May 5, 2015</results_first_submitted>
  <results_first_submitted_qc>July 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2015</results_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, Pandemic, H5N1, Elderly adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1393 subjects were enrolled at 12 centers in the US, 5 centers in Australia, 2 centers in New Zealand and 4 centers in Thailand.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose</title>
          <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose</title>
          <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="700"/>
                <participants group_id="P2" count="693"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="676"/>
                <participants group_id="P2" count="676"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was done on All Enrolled population.</population>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose</title>
          <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="700"/>
            <count group_id="B2" value="693"/>
            <count group_id="B3" value="1393"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.2" spread="5.1"/>
                    <measurement group_id="B2" value="70.7" spread="4.7"/>
                    <measurement group_id="B3" value="71.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="407"/>
                    <measurement group_id="B2" value="418"/>
                    <measurement group_id="B3" value="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.</title>
        <description>The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.
The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 60%.</description>
        <time_frame>Baseline (day 1) and Three weeks after 2nd vaccination (day 43)</time_frame>
        <population>Analysis was done on the Full Analysis Set (FAS) i.e., subjects who actually receive at least one dose of study vaccination and provide at least one evaluable serum sample both before (baseline) and after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.</title>
          <description>The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.
The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 60%.</description>
          <population>Analysis was done on the Full Analysis Set (FAS) i.e., subjects who actually receive at least one dose of study vaccination and provide at least one evaluable serum sample both before (baseline) and after vaccination.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=673,664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="78" upper_limit="84"/>
                    <measurement group_id="O2" value="63" lower_limit="59" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</title>
        <description>Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.
Seroconversion is defined as, a postvaccination titer ≥40 in subjects with a prevaccination HI titer &lt;10; or in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 30%.</description>
        <time_frame>Three weeks after 2nd vaccination (day 43)</time_frame>
        <population>This analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.</title>
          <description>Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.
Seroconversion is defined as, a postvaccination titer ≥40 in subjects with a prevaccination HI titer &lt;10; or in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 30%.</description>
          <population>This analysis was done on the FAS.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="673"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="70" upper_limit="77"/>
                    <measurement group_id="O2" value="52" lower_limit="48" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events, After Any Vaccination.</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following vaccination with either low or high dose of aH5N1c vaccine.</description>
        <time_frame>From day 1 through day 7 after any vaccination.</time_frame>
        <population>Analysis was done on the solicited safety population, i.e. All subjects in the exposed set with solicited (local/systemic) AE data..</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events, After Any Vaccination.</title>
          <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following vaccination with either low or high dose of aH5N1c vaccine.</description>
          <population>Analysis was done on the solicited safety population, i.e. All subjects in the exposed set with solicited (local/systemic) AE data..</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N=693,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration (N=693,683)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Ecchymosis (N=692,682)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Pain (N=693,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=692,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=691,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=692,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=692,678)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=692,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite (N=683,673)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=692,680)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C; N=693,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain and (or) Fever (N=691,682)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain and (or) Fever (N=691,682)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.</title>
        <description>Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with aH5N1c vaccine</description>
        <time_frame>Day 1 through day 387 after any vaccination</time_frame>
        <population>Analysis was done unsolicited safety population, i.e. subjects in the exposed set with unsolicited AE data.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.</title>
          <description>Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with aH5N1c vaccine</description>
          <population>Analysis was done unsolicited safety population, i.e. subjects in the exposed set with unsolicited AE data.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="686"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs (Day 1 to 22; N=694,685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs(Day1to22;N=694,685)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs (Day 23 to 43; N=689,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs(Day23to43;N=689,681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383"/>
                    <measurement group_id="O2" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature withdrawal from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios (GMR) Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.</title>
        <description>Immunogenicity was measured as the GMR. The ratio of postvaccination to prevaccination HI geometric mean titers (GMTs) is reported.
The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is &gt;2.0 for subjects &gt;60 years of age.</description>
        <time_frame>Day 1; day 22; day 43 and day 387</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMR) Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.</title>
          <description>Immunogenicity was measured as the GMR. The ratio of postvaccination to prevaccination HI geometric mean titers (GMTs) is reported.
The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is &gt;2.0 for subjects &gt;60 years of age.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H5N1 (Day22/Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="2.85" upper_limit="3.62"/>
                    <measurement group_id="O2" value="2.01" lower_limit="1.78" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H5N1 (Day43/Day1; N=673,664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="O2" value="5.72" lower_limit="4.94" upper_limit="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H5N1 (Day387/Day1; N=658,651)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.79" upper_limit="2.17"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.18" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain</title>
        <description>Immunogenicity was assessed in terms of percentage of subjects achieving HI titers &gt;40, three weeks after second vaccination with aH5N1c according to the CHMP criterion.
The European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;60%.</description>
        <time_frame>Day 1, day 22, day 43 and day 387.</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain</title>
          <description>Immunogenicity was assessed in terms of percentage of subjects achieving HI titers &gt;40, three weeks after second vaccination with aH5N1c according to the CHMP criterion.
The European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers ≥40 is &gt;60%.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (N=681,673)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="45" upper_limit="52"/>
                    <measurement group_id="O2" value="32" lower_limit="28" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=673,664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="78" upper_limit="84"/>
                    <measurement group_id="O2" value="63" lower_limit="59" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 387 (N=658,651)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="31" upper_limit="39"/>
                    <measurement group_id="O2" value="16" lower_limit="13" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, three weeks after receiving two injections of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.
Seroconversion is defined as a postvaccination titer ≥40 in subjects with a prevaccination HI titer &lt;10; or in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion is &gt;30%.</description>
        <time_frame>Day 22, day 43 and day 387</time_frame>
        <population>Analysis was done on the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, three weeks after receiving two injections of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.
Seroconversion is defined as a postvaccination titer ≥40 in subjects with a prevaccination HI titer &lt;10; or in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.
The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion is &gt;30%.</description>
          <population>Analysis was done on the FAS.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="32" upper_limit="40"/>
                    <measurement group_id="O2" value="21" lower_limit="18" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (N=673,664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="70" upper_limit="77"/>
                    <measurement group_id="O2" value="52" lower_limit="48" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 387 (N=658,651)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="20" upper_limit="27"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and systemic adverse events were collected from day 1 to 7. Unsolicited AEs (other than SAEs) and SAEs were collected from day 1 to 387.</time_frame>
      <desc>All Solicited AEs-systematic assessment and all unsolicited AEs-non-systematic assessment.
Type II reactions are reported for solicited AEs. Total number of subjects enrolled was - High dose: 700 and Low dose: 693. Total number of subjects who received a study vaccination and included in safety set was - High dose: 699 and Low dose: 689</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>Subjects received 2 injections of a high dose MF59 adjuvanted cell-culture derived monovalent H5N1 vaccine three weeks apart.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Subjects received 2 injections of a low dose MF59 adjuvanted cell-culture derived monovalent H5N1 three weeks apart.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total of subjects in both high and low dose groups.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>STRESS CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>EPIPLOIC APPENDAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BONE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>LENTIGO MALIGNA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BASAL GANGLIA INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>BRAIN STEM INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>GRIEF REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>RECTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="481" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="427" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="908" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="236" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="527" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="235" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="174" subjects_at_risk="1388"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="196" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="689"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="1388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

